COMPANY
Keywords: immunology oncology infectious disease diagnostics Immunity to COVID-19 Antibody-Mediated Graft Rejection
Location: Pittsburgh, PA · source · Oct 14, 2026
Profile checked Oct 10, 2026
Timeline
- Trial start —: Immunity After COVID-19 Vaccination source ↗
- Trial start —: Cell-based Assays for Antibody-mediated Transplant Rejection source ↗
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT04883164 | Immunity After COVID-19 Vaccination | Not listed | Unknown status (ClinicalTrials.gov) | Apr 27, 2021 | Mar 31, 2023 (estimated) |
| NCT03916822 | Cell-based Assays for Antibody-mediated Transplant Rejection | Not listed | Unknown status (ClinicalTrials.gov) | Apr 15, 2019 | Jun 14, 2021 (estimated) |